600 related articles for article (PubMed ID: 33740877)
1. Hallucinogenic/psychedelic 5HT2A receptor agonists as rapid antidepressant therapeutics: Evidence and mechanisms of action.
Dos Santos RG; Hallak JE; Baker G; Dursun S
J Psychopharmacol; 2021 Apr; 35(4):453-458. PubMed ID: 33740877
[TBL] [Abstract][Full Text] [Related]
2. Spectral signatures of serotonergic psychedelics and glutamatergic dissociatives.
Pallavicini C; Vilas MG; Villarreal M; Zamberlan F; Muthukumaraswamy S; Nutt D; Carhart-Harris R; Tagliazucchi E
Neuroimage; 2019 Oct; 200():281-291. PubMed ID: 31247301
[TBL] [Abstract][Full Text] [Related]
3. [Contribution of serotonin 5-HT
Ibi D
Nihon Yakurigaku Zasshi; 2023 May; 158(3):229-232. PubMed ID: 36990794
[TBL] [Abstract][Full Text] [Related]
4. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews.
Dos Santos RG; Bouso JC; Alcázar-Córcoles MÁ; Hallak JEC
Expert Rev Clin Pharmacol; 2018 Sep; 11(9):889-902. PubMed ID: 30102078
[TBL] [Abstract][Full Text] [Related]
5. Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: A systematic review and meta-analysis.
Leger RF; Unterwald EM
J Psychopharmacol; 2022 Jan; 36(1):20-30. PubMed ID: 34519567
[TBL] [Abstract][Full Text] [Related]
6. Psychedelics for treatment resistant depression: are they game changers?
Kalfas M; Taylor RH; Tsapekos D; Young AH
Expert Opin Pharmacother; 2023; 24(18):2117-2132. PubMed ID: 37947195
[TBL] [Abstract][Full Text] [Related]
7. d-Lysergic acid diethylamide, psilocybin, and other classic hallucinogens: Mechanism of action and potential therapeutic applications in mood disorders.
De Gregorio D; Enns JP; Nuñez NA; Posa L; Gobbi G
Prog Brain Res; 2018; 242():69-96. PubMed ID: 30471683
[TBL] [Abstract][Full Text] [Related]
8. Ethopharmacological evaluation of antidepressant-like effect of serotonergic psychedelics in C57BL/6J male mice.
Takaba R; Ibi D; Yoshida K; Hosomi E; Kawase R; Kitagawa H; Goto H; Achiwa M; Mizutani K; Maeda K; González-Maeso J; Kitagaki S; Hiramatsu M
Naunyn Schmiedebergs Arch Pharmacol; 2024 May; 397(5):3019-3035. PubMed ID: 37874338
[TBL] [Abstract][Full Text] [Related]
9. [Classic psychedelic drugs and their potential therapeutic effect].
Bayat M
Ugeskr Laeger; 2017 Sep; 179(37):. PubMed ID: 28918777
[TBL] [Abstract][Full Text] [Related]
10. Psychedelics, but Not Ketamine, Produce Persistent Antidepressant-like Effects in a Rodent Experimental System for the Study of Depression.
Hibicke M; Landry AN; Kramer HM; Talman ZK; Nichols CD
ACS Chem Neurosci; 2020 Mar; 11(6):864-871. PubMed ID: 32133835
[TBL] [Abstract][Full Text] [Related]
11. Antidepressant-like effects of psychedelics in a chronic despair mouse model: is the 5-HT
Sekssaoui M; Bockaert J; Marin P; Bécamel C
Neuropsychopharmacology; 2024 Mar; 49(4):747-756. PubMed ID: 38212441
[TBL] [Abstract][Full Text] [Related]
12. The possible place for psychedelics in pharmacotherapy of mental disorders.
Wojtas A
Pharmacol Rep; 2023 Dec; 75(6):1313-1325. PubMed ID: 37934320
[TBL] [Abstract][Full Text] [Related]
13. Mescaline: The forgotten psychedelic.
Vamvakopoulou IA; Narine KAD; Campbell I; Dyck JRB; Nutt DJ
Neuropharmacology; 2023 Jan; 222():109294. PubMed ID: 36252614
[TBL] [Abstract][Full Text] [Related]
14. Psychedelics and Hallucinogens in Psychiatry: Finding New Pharmacological Targets.
Sousa TR; Rema J; Machado S; Novais F
Curr Top Med Chem; 2022; 22(15):1250-1260. PubMed ID: 34852736
[TBL] [Abstract][Full Text] [Related]
15. No trip needed for psychedelics to lift mood?
O'Grady C
Science; 2023 Jun; 380(6649):999. PubMed ID: 37289868
[TBL] [Abstract][Full Text] [Related]
16. A Critical Appraisal of Evidence on the Efficacy and Safety of Serotonergic Psychedelic Drugs as Emerging Antidepressants: Mind the Evidence Gap.
Ledwos N; Rosenblat JD; Blumberger DM; Castle DJ; McIntyre RS; Mulsant BH; Husain MI
J Clin Psychopharmacol; 2022 Nov-Dec 01; 42(6):581-588. PubMed ID: 36193898
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological and biotransformation studies of 1-acyl-substituted derivatives of d-lysergic acid diethylamide (LSD).
Halberstadt AL; Chatha M; Klein AK; McCorvy JD; Meyer MR; Wagmann L; Stratford A; Brandt SD
Neuropharmacology; 2020 Aug; 172():107856. PubMed ID: 31756337
[TBL] [Abstract][Full Text] [Related]
18. Antidepressant Effects of Psilocybin in the Absence of Psychedelic Effects.
Rosenblat JD; Leon-Carlyle M; Ali S; Husain MI; McIntyre RS
Am J Psychiatry; 2023 May; 180(5):395-396. PubMed ID: 36945824
[No Abstract] [Full Text] [Related]
19. Therapeutic use of serotoninergic hallucinogens: A review of the evidence and of the biological and psychological mechanisms.
Dos Santos RG; Hallak JEC
Neurosci Biobehav Rev; 2020 Jan; 108():423-434. PubMed ID: 31809772
[TBL] [Abstract][Full Text] [Related]
20. Hallucinogens and Serotonin 5-HT
López-Giménez JF; González-Maeso J
Curr Top Behav Neurosci; 2018; 36():45-73. PubMed ID: 28677096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
